Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.57
-0.5%
$14.58
$10.81
$18.06
$287.39M1.1451,073 shs16,857 shs
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
$0.38
$0.38
$0.26
$1.30
$67.96M0.747,701 shs29,889 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$4.85
-0.4%
$3.58
$1.87
$11.40
$423.69M-0.111.17 million shs315,754 shs
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$5.00
$5.00
$2.29
$5.30
$266.15M1.04648,490 shsN/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-1.14%+0.51%+9.44%+29.88%+7.78%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.00%0.00%0.00%0.00%0.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-0.41%+15.13%+19.95%+127.57%-33.29%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
0.00%0.00%0.00%+0.81%+29.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
2.0278 of 5 stars
2.53.00.00.03.02.50.0
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
N/AN/AN/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.7906 of 5 stars
3.31.00.04.11.63.30.0
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$18.3317.76% Upside
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.00
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63222.16% Upside
2seventy bio, Inc. stock logo
TSVT
2seventy bio
2.00
Hold$5.00N/A

Current Analyst Ratings Breakdown

Latest PYR, NATR, TERN, and TSVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
5/10/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/7/2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
4/24/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
4/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
4/14/2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$454.36M0.63$1.23 per share12.67$8.71 per share1.79
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
$14.63M4.65N/AN/A$0.07 per share5.43
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.07 per shareN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$48.37M5.50N/AN/A$5.04 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$7.70M$0.5329.37N/A2.22%6.98%4.63%8/6/2025 (Estimated)
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
-$24.74M-$0.11N/AN/A-233.18%-194.66%-68.91%N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)

Latest PYR, NATR, TERN, and TSVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.05N/AN/AN/A$15.45 millionN/A
8/4/2025Q2 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
5/7/2025Q1 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million
5/6/2025Q1 2025
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$0.16$0.25+$0.09$0.25$109.39 million$113.25 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.41
1.50
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.26
0.86
0.78
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
30.89
30.89
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/A
4.95
4.95

Institutional Ownership

CompanyInstitutional Ownership
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.41%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
93.90%

Insider Ownership

CompanyInsider Ownership
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
4.70%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
47.68%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
85018.46 million17.60 millionOptionable
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
2,020178.88 million93.59 millionNot Optionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million86.03 millionNot Optionable
2seventy bio, Inc. stock logo
TSVT
2seventy bio
44053.23 million47.87 millionOptionable

Recent News About These Companies

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
2seventy bio accepts Bristol Myers’ takeover bid
2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Nature's Sunshine Products stock logo

Nature's Sunshine Products NASDAQ:NATR

$15.57 -0.08 (-0.52%)
As of 12:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYR

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. It offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. The company also provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montréal, Canada.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$4.85 -0.02 (-0.41%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

2seventy bio stock logo

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)
As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.